Caris Life Sciences announced the launch of ChromoSeq, a new assay that integrates whole‑genome sequencing (WGS) and whole‑transcriptome sequencing (WTS) to diagnose myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. The test delivers approximately 250× read depth across the genome and 40 million transcriptome reads from a single bone‑marrow aspirate or peripheral blood sample, producing an actionable report in about seven days.
The launch expands Caris’s comprehensive profiling platform into a high‑complexity hematologic space, a move that could increase its market share in oncology diagnostics. By replacing multiple fragmented tests, ChromoSeq streamlines the diagnostic workflow, potentially accelerating clinical decision‑making and improving detection of clinically relevant mutations, structural variants, and chromosomal abnormalities in a complex disease area.
Caris’s broader strategy has been underpinned by a 740,000‑record multimodal database and AI‑driven analytics. The company’s recent financial performance—97% revenue growth over the last twelve months to $812 million and a Q4 2025 revenue of $293 million, up 125% YoY—reflects strong demand for its diagnostic solutions. A 150% increase in clinical average selling price contributed to the revenue surge, underscoring pricing power in the diagnostics market.
Management highlighted the assay’s value: “The Caris ChromoSeq launch provides an unprecedented amount of genomic and transcriptomic data per patient, enabling a complete diagnostic evaluation in a single test.” The integrated approach positions Caris against competitors such as Foundation Medicine, Tempus AI, and Guardant Health, offering a unique combination of WGS and WTS that can uncover a broader spectrum of actionable alterations.
While the launch is a strategic milestone, analysts note that Caris faces operating‑expense pressures and a competitive landscape that could temper growth. Nonetheless, the company’s AI insights and extensive data assets are expected to support continued expansion in the diagnostics sector.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.